MESOTELIOMA

PROMISE-Meso
BEAT-Meso
BIMES

PROMISE-Meso

Multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma.

Promotor: ETOP
Coordinador en España: Dr. Ernest Nadal

Centros participantes

Institut Català d’Oncologia-Hospitalet
Hospital Clínico Universitario de Valladolid
Hospital Teresa Herrera, A Coruña

BEAT-Meso

A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment in advanced malignant pleural mesothelioma

Promotor: ETOP
Coordinador en España: Dr. Enriqueta Felip and Dr. Sanjay Popat

Centros participantes

Hospital Parc Taulí Sabadell
Hospital Univ. Virgen del Rocio
Hospital Univ. General de Alicante
Complejo Hospitalario de Vigo
Hospital Univ. Puerta de Hierro
Hospital Univ. Vall d’Hebron
ICO Hospitalet

BIMES

A phase II single arm clinical trial assessing the efficacy and safety of BIntrafusp alfa (M7824) in previously treated advanced malignant pleural MESothelioma (BIMES)”.

Promotor: GECP
Coordinador: Dr. Ernest Nadal

Nº pacientes previstos: 47
Nº centros participantes: 15

Centros participantes

ICO-Bellvitge
Hospital General de Alicante
ICO-Girona
Hospital Univ. Fundación Jiménez Díaz
ICO-Badalona
Complejo Hospitalario de la Coruña
H. de Basurto
Hospital Univ. Lucus Agustí
Consorcio Sanitario Parc Taulí
Hospital Clín. Univ. de Valencia
Hospital Clín. Univ. de Valladolid
Hospital Univ. Vall Hebrón
Hospital Central de Asturias
Hospital Univ. Puerta de Hierro
Hospital Univ. Virgen de la Victoria